WO2003048393A1 - Mixture of two partially denaturating agents for the preparation of pcr buffer solutions - Google Patents
Mixture of two partially denaturating agents for the preparation of pcr buffer solutions Download PDFInfo
- Publication number
- WO2003048393A1 WO2003048393A1 PCT/IT2001/000611 IT0100611W WO03048393A1 WO 2003048393 A1 WO2003048393 A1 WO 2003048393A1 IT 0100611 W IT0100611 W IT 0100611W WO 03048393 A1 WO03048393 A1 WO 03048393A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dmso
- buffer solutions
- dna
- pcr buffer
- mixture
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Definitions
- the invention concerns DNA amplification techniques and more particularly the use, in buffer solutions for the polymerase chain reaction (PCR) , of a new mixture of two partially 5 denaturating agents: glycerol and dimetyl sulfoxide (DMSO) . These two agents are able to facilitate DNA denaturation and to minimise, at the same time, the disadvantages related to the use of denaturating agents in PCR buffer 10 solutions.
- PCR polymerase chain reaction
- the PCR process comprises three subsequent steps, which are repeated at every single denaturation cycle:
- DNA polymerase the enzyme responsible for DNA replication
- the first denaturation step is surely the main reaction and without it the amplification cycle can not proceed.
- the double elix of DNA loses its primary structure due to hydrogen bounds between nucleotides and hydrophobic interactions between stacked basis and it loses the secondary structures due to close complementary sequences which, within the same molecule, form loops or crosses.
- DNA denaturation is induced by temperature increasing, by using chemical agents which destabilised the double elix structure or by using extreme pH conditions that gives to nucleotides a net charge and enhance denaturation .
- formamides The best known and common denaturating agents are formamides, non ionic detergents and dimetylsulfoxide (DMSO) . These compounds have many disadvantages, for example: formamides damages polymerase physical -chemical characteristics; non ionic detergents enhance aspecific amplification rate.
- DMSO dimetylsulfoxide
- DMSO causes DNA breaking and polymerase inactivation, on the other hand, it drastically reduces the formation of secondary structures that stop polymerase progression during replication, and furthermore it can induce CG- rich regions denaturation and can improve annealing specificity of the primer-template complex creating more strict reaction conditions, ensuring the bound between each primer and the corresponding DNA sequence .
- the present invention overcomes the problems related to the use of denaturating agents, like DMSO, in the preparation of PCR buffer solution, providing a new mixture for the preparation of PCR buffer solutions able to reduce DMSO rate and containing compounds enabling the denaturation to be executed at a lower temperature, it can stabilises DNA polymerase and it reduces the risk of incorrect annealing.
- denaturating agents like DMSO
- Glycerol a) It's a co-solvent that allows the denaturation reaction to be carried out at lower temperatures. b) It stabilises DNA polimerase c) It reduces false-priming that occurs when primers bound to sequence different from the one to be amplified. This characteristic is very important in multiplex PCR when a large number of primers must bound each to a precise template sequence.
- DMSO a) It helps DNA denaturation especially of GC- rich regions; b) It improves specificity pairing between primers and templates.
- DMSO in low concentrations does not damage DNA polymerase (which is quite expensive) enabling the use of lower amounts of the enzyme; it offers an high rate of amplification trough regions of the DNA molecule having different danaturation profiles, and it renders the entire process cheaper; it further avoids the formation of intrachain bounds that stop polymerase progression during replication; it permits the use of a concentration of DMSO which is lower than the one commonly used in buffer solutions in the state of the art, avoiding damages of the DNA molecule to be amplified and the risk of enzymes inactivation; it reduces dangerous false-priming between primers and templates, useful particularly in long PCR when the sequences to be amplified have a length up to 18.000 bais pairs; it allows to have a good DNA polymerase processivity even after long periods of exposure to high temperatures and/or the same denaturating agents .
- Figure 1 compares the results obtained from a PCR in presence of a buffer solution containing only glycerol at different concentration with those obtained from a PCR in presence of a buffer solution containing glycerol in a concentration of 1% together with DMSO at different concentrations.
- Axis of ordinates represent band intensity of an electrophoresis test of amplified samples, the minimum amplified quantity is normalised at value 1.
- the mixture, object of the present invention is characterised in containing a very low amount of DMSO.
- the mixture, in the final concentration used for the amplification reaction is as follows: DMSO from 0.8 to 1.5 % GLYCEROL from 7 to 9 %
- the mixture, object of the present invention is characterised in having the following composition in the final concentration used for the amplification reaction:
- PCR buffer solutions containing the mixture of partially denaturating agents, object of the present invention are extremely suitable for GC- rich regions PCR, for multiplex PCR and for Long PCR.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IT2001/000611 WO2003048393A1 (en) | 2001-12-04 | 2001-12-04 | Mixture of two partially denaturating agents for the preparation of pcr buffer solutions |
AU2002217428A AU2002217428A1 (en) | 2001-12-04 | 2001-12-04 | Mixture of two partially denaturating agents for the preparation of pcr buffer solutions |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IT2001/000611 WO2003048393A1 (en) | 2001-12-04 | 2001-12-04 | Mixture of two partially denaturating agents for the preparation of pcr buffer solutions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003048393A1 true WO2003048393A1 (en) | 2003-06-12 |
Family
ID=11133761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IT2001/000611 WO2003048393A1 (en) | 2001-12-04 | 2001-12-04 | Mixture of two partially denaturating agents for the preparation of pcr buffer solutions |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002217428A1 (en) |
WO (1) | WO2003048393A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2912151A1 (en) * | 2007-02-05 | 2008-08-08 | Arkema France | Crystallization point lowering additive for dimethyl sulfoxide, e.g. during use as paint stripper or surface cleaner, comprises diol and/or triol, especially glycerol |
US10858696B2 (en) | 2014-06-02 | 2020-12-08 | Illumina Cambridge Limited | Methods of reducing density-dependent GC bias in amplification |
US11591643B2 (en) | 2016-06-30 | 2023-02-28 | Lumiradx Uk Ltd. | In or relating to uncleic acid amplification processes |
US11655496B2 (en) | 2018-01-04 | 2023-05-23 | Lumiradx Uk Ltd. | Amplification of nucleic acids |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0669401A2 (en) * | 1994-02-25 | 1995-08-30 | F. Hoffmann-La Roche Ag | Amplification of long nucleic acid sequences by PCR |
-
2001
- 2001-12-04 AU AU2002217428A patent/AU2002217428A1/en not_active Abandoned
- 2001-12-04 WO PCT/IT2001/000611 patent/WO2003048393A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0669401A2 (en) * | 1994-02-25 | 1995-08-30 | F. Hoffmann-La Roche Ag | Amplification of long nucleic acid sequences by PCR |
Non-Patent Citations (1)
Title |
---|
CHENG S ET AL: "EFFECTIVE AMPLIFICATION OF LONG TARGETS FROM CLONED INSERTS AND HUMAN GENOMIC DNA", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 91, no. 12, June 1994 (1994-06-01), pages 5695 - 5699, XP000982285, ISSN: 0027-8424 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2912151A1 (en) * | 2007-02-05 | 2008-08-08 | Arkema France | Crystallization point lowering additive for dimethyl sulfoxide, e.g. during use as paint stripper or surface cleaner, comprises diol and/or triol, especially glycerol |
WO2008107611A3 (en) * | 2007-02-05 | 2008-11-06 | Arkema France | Dimethylsulfoxide formulation in mixture with additive for lowering the crystallization point of same, and applications of said mixture |
US7959767B2 (en) | 2007-02-05 | 2011-06-14 | Arkema France | Dimethyl sulfoxide formulation in mixture with additive for lowering the crystallization point of same, and applications of said mixture |
US8741826B2 (en) | 2007-02-05 | 2014-06-03 | Arkema France | Dimethylsulfoxide formulation in mixture with additive for lowering the crystallization point of same, and applications of said mixture |
EP3795648A1 (en) | 2007-02-05 | 2021-03-24 | Gaylord Chemical Company LLC | Formulation of dimethyl sulfoxide in mixture with an additive capable of reducing the crystallisation point of the latter, and uses of said mixture |
US10858696B2 (en) | 2014-06-02 | 2020-12-08 | Illumina Cambridge Limited | Methods of reducing density-dependent GC bias in amplification |
US11591643B2 (en) | 2016-06-30 | 2023-02-28 | Lumiradx Uk Ltd. | In or relating to uncleic acid amplification processes |
US11655496B2 (en) | 2018-01-04 | 2023-05-23 | Lumiradx Uk Ltd. | Amplification of nucleic acids |
Also Published As
Publication number | Publication date |
---|---|
AU2002217428A1 (en) | 2003-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3298170B1 (en) | Methods for generating circular dna from circular rna | |
AU2012307282B2 (en) | Nucleic acid transcription method | |
JP3867926B2 (en) | Nucleic acid amplification method | |
EP3256584B1 (en) | Method and compositions for reducing non-specific amplification products | |
JP5702148B2 (en) | Reduced inhibition of 1-step RT-PCR | |
WO2017141067A1 (en) | Method of eliminating background amplification of nucleic acid targets | |
US20170362623A1 (en) | Amplification of nucleic acids | |
WO2010026933A1 (en) | Composition for detection of rna | |
CN110506114B (en) | PCR primer pair and application thereof | |
WO2003048393A1 (en) | Mixture of two partially denaturating agents for the preparation of pcr buffer solutions | |
JP7106461B2 (en) | Thermostable polymerase inhibitor compositions and methods | |
JPWO2002036822A1 (en) | Nucleic acid base sequencing method | |
Asif et al. | PCR Optimization for Beginners: A Step by Step Guide | |
AU2016231995A1 (en) | PCR method | |
Best et al. | Molecular pathology methods | |
Panelli et al. | Ligation overcomes terminal underrepresentation in multiple displacement amplification of linear DNA | |
WO2017088750A1 (en) | Method and kit for deviation amplification of target nucleic acid sequence in sample | |
EP4010493A1 (en) | Methods for the multiplexed isothermal amplification of nucleic acid sequences | |
JP7191115B2 (en) | Method for amplification of nucleic acids by endonuclease-mediated migration equilibrium (EM-SEq) | |
JP4104285B2 (en) | DNA amplification method and kit thereof | |
US20140329702A1 (en) | Method of amplifying a nucleic acid | |
US20230340462A1 (en) | Method for producing dna molecules having an adaptor sequence added thereto, and use thereof | |
JP2022170729A (en) | Novel method for preparing gene libraries | |
CN112359031A (en) | Hot-start DNA polymerase and preparation method and application thereof | |
JP2005102502A (en) | Method for amplifying single-stranded nucleic acid fragment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |